Phthalates and bisphenols early-life exposure, and childhood allergic conditions: a pooled analysis of cohort studies
- PMID: 40610791
- PMCID: PMC12583191
- DOI: 10.1038/s41370-025-00790-2
Phthalates and bisphenols early-life exposure, and childhood allergic conditions: a pooled analysis of cohort studies
Abstract
Background: Exposure to plastic additives, such as phthalates and bisphenols, has been associated with a higher risk of allergic conditions, but the evidence is inconsistent for children younger than five.
Objective: To examine the association between pre- and postnatal urinary phthalates and bisphenols, and allergic conditions, and potential effect modification by sex, in pre-school children, through a pooled analysis.
Methods: We pooled data from the Barwon Infant Study (Australia), the Canadian Healthy Infant Longitudinal Development Study (Canada), the Health Outcomes and Measures of the Environment (United States) and the Environmental Influences on Child Health Outcomes-wide cohorts (United States). Urinary phthalates and bisphenols were measured during pregnancy and early childhood. We estimated daily intakes from urinary concentrations, except for mono-(3-carboxypropyl) phthalate (MCPP). Outcomes, including asthma, wheeze, eczema, and rhinitis, were assessed up to five years of age through questionnaires and clinical assessments. We used generalised estimating equations for single compounds and quantile G-computation for the chemical mixtures.
Results: 5306 children were included. A two-fold increase in prenatal dibutyl phthalates (DBP; risk ratio [RR] = 1.08; 95% confidence interval [CI]: 1.00-1.16) and benzyl butyl phthalate (BBzP; RR = 1.06; 95%CI: 1.00-1.12) increased the risk of asthma in children under five. Prenatal MCPP levels were associated with rhinitis (RR = 1.05; 95%CI: 1.01-1.09). Postnatal BBzP levels increased the risk of wheezing (RR = 1.05; 95%CI 1.01-1.09), as well as di(2-ethylhexyl) phthalate (DEHP; RR = 1.06; 95%CI: 1.01-1.11) and MCPP (RR = 1.09; 95%CI: 1.04-1.14). These were also inversely associated with eczema. A one-quartile increase in the postnatal chemical mixture increased the risk of wheezing (RR = 1.14; 95%CI: 1.02-1.26). There was limited evidence of effect modification by sex.
Impact: Phthalates and bisphenols are widespread and may contribute to allergic conditions in children. We pooled data from 5000 children across multiple birth cohorts, suggesting that early-life exposure to these chemicals is associated with increased risks of asthma, wheezing, and rhinitis by age five. We further investigated the timing of exposure, non-linear dose-response relationships, and effect measure modification by sex. This study provides a comprehensive assessment of early-life exposure to phthalates and bisphenols and strengthens the evidence for their role in the development of childhood allergic outcomes.
Keywords: Allergies; Asthma; Bisphenols; Children; Phthalates; Pooled-analysis.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: Joseph Braun was compensated for serving as an expert witness for plaintiffs in litigation related to PFAS-contaminated drinking water. All other authors declare they have no conflicts of interest related to this work to disclose. Ethical approval: All participants in the included cohorts provided written informed consent before enrolment. Ethical approval for each study was obtained from the relevant institutional review boards: the Barwon Infant Study was approved by the Barwon Health Human Research Ethics Committee (HREC 10/24); the HOME Study was approved by the Institutional Review Boards of Cincinnati Children’s Hospital Medical Centre, cooperating delivery hospitals, and the U.S. Centre for Disease Control and Prevention (CDC); local Research Ethics Boards approved the CHILD Cohort Study at participating institutions; and the Western Institutional Review Board approved the ECHO-wide Cohort Protocol (version 1.2). All study procedures were conducted in accordance with applicable institutional and national ethical guidelines and regulations.
Figures
References
-
- World Health O, United Nations Environment P, Inter-Organization Programme for the Sound Management of C, Bergman Å, Heindel JJ, Jobling S, et al. State of the science of endocrine disrupting chemicals 2012: summary for decision-makers. Technical documents. World Health Organization; 2013 2013.
MeSH terms
Substances
Grants and funding
- UH3 OD023286/OD/NIH HHS/United States
- UH3 OD023271/OD/NIH HHS/United States
- UH3 OD023348/OD/NIH HHS/United States
- UH3 OD023248/OD/NIH HHS/United States
- U24 OD023319/OD/NIH HHS/United States
- UH3 OD023305/OD/NIH HHS/United States
- UH3 OD023347/OD/NIH HHS/United States
- UH3 OD023288/OD/NIH HHS/United States
- UH3 OD023342/OD/NIH HHS/United States
- UH3 OD023268/OD/NIH HHS/United States
- UH3 OD023337/OD/NIH HHS/United States
- UH3 OD023328/OD/NIH HHS/United States
- U2C ES026533/ES/NIEHS NIH HHS/United States
- U24 OD023382/OD/NIH HHS/United States
- UH3 OD023313/OD/NIH HHS/United States
- U2C ES026544/ES/NIEHS NIH HHS/United States
- UH3 OD023289/OD/NIH HHS/United States
- UH3 OD023332/OD/NIH HHS/United States
- U2C ES026542/ES/NIEHS NIH HHS/United States
- U2C ES026555/ES/NIEHS NIH HHS/United States
- U2C ES030857/ES/NIEHS NIH HHS/United States
- U2C ES026561/ES/NIEHS NIH HHS/United States
- UH3 OD023249/OD/NIH HHS/United States
- UH3 OD023389/OD/NIH HHS/United States
- UH3 OD023290/OD/NIH HHS/United States
- U2C OD023375/OD/NIH HHS/United States
- U24 ES026539/ES/NIEHS NIH HHS/United States
- UH3 OD023285/OD/NIH HHS/United States
- UH3 OD023344/OD/NIH HHS/United States
- UH3 OD023275/OD/NIH HHS/United States
- UH3 OD023318/OD/NIH HHS/United States
- UH3 OD023282/OD/NIH HHS/United States
- P01 ES011261/ES/NIEHS NIH HHS/United States
- UH3 OD023287/OD/NIH HHS/United States
- UG3 OD023251/OD/NIH HHS/United States
- R01 ES014575/ES/NIEHS NIH HHS/United States
- P30 ES013508/ES/NIEHS NIH HHS/United States
- UH3 OD023253/OD/NIH HHS/United States
- UH3 OD023272/OD/NIH HHS/United States
- UH3 OD023251/OD/NIH HHS/United States
- UH3 OD023279/OD/NIH HHS/United States
- UH3 OD023244/OD/NIH HHS/United States
- UH3 OD023320/OD/NIH HHS/United States
- R01 ES024381/ES/NIEHS NIH HHS/United States
- UH3 OD023349/OD/NIH HHS/United States
- UH3 OD023365/OD/NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
